Background: Epidemiological and experimental evidence suggest that serum uric acid is an important independent risk factor for cardiovascular and renal disease especially in patients with hypertension.In contrast to other angiotensin II antagonists, Losartan has unique pleiotropic uricosuric property and thereby reducing the risk of future cardiovascular complications in hypertensive patients.
Aim: To study the uricosuric effects of losartan in newly diagnosed hypertensive patients with hyperuricaemia.
Methodology: Open label, prospective and interventional study done after IEC approval. Newly diagnosed patients with stage 1 and stage 2 essential hypertension with hyperuricaemia who fulfilled the inclusion criteria were enrolled for the study and given Losartan. At the end of 4th week all the baseline laboratory parameters like renal function test, liver function test, and serum uric acid and urinary uric acid excretion were performed and results were analysed statistically
Results: After Losartan therapy mean serum uric acid was reduced from 6.43mg/dl to 5.33mg/dl and mean urinary uric acid excretion was increased from 418.12mg/day to 467.84mg/day which was significant.
Impact Factor
2022: 6.012
This work is licensed under a